Compare IDEXX Laboratories, Inc. (IDXX) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Marathon Petroleum Corp — how do they compare? IDEXX Laboratories, Inc. trades at $554.7 (market cap $44.48B), while Marathon Petroleum Corp trades at $317.84 (market cap $92.05B). The key difference: Marathon Petroleum Corp is far larger — about 2.1× IDEXX Laboratories, Inc.'s market cap, and Marathon Petroleum Corp pays a 1.24% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| IDXX | MPC | |
|---|---|---|
Market Cap | $44.48B | $92.05B |
Sector | Health | Energy |
52-Week High | $766.68 | $315.31 |
52-Week Low | $520.87 | $158.59 |
Enterprise Value | $45.38B | $124.23B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
Marathon Petroleum (MPC) trades at $317.00, up 1.41% today, reflecting strong momentum amid bullish technical signals and positive analyst sentiment. The stock shows robust fundamentals with a P/E of 20.58, P/S of 0.7, and ROE of 27.92%, supported by recent earnings beats in Q4 2025 and Q1 2026. Cash flow trends indicate operational strength with $8.25B from operations in 2025, while refining margins drive profitability, as highlighted in recent Zacks reports (July 2026).
Outlook remains positive with 76% analyst buy ratings and a consensus price target of $292.70, though risks include volatile energy markets and rising debt-to-asset ratios. The stock's proximity to resistance at $317 suggests potential consolidation, but sustained refining advantages and institutional support offer upside potential for investors focused on energy sector growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
